Navigation Links
Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
Date:10/27/2010

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly ADP-Ribose Polymerase (PARP) inhibitor drug class.  

The Pharmacor 2010 findings from the topic entitled Breast Cancer reveal that Sanofi-Aventis's PARP inhibitor iniparib has the potential to achieve blockbuster peak-year sales in excess of $1 billion. In addition to iniparib, other key PARP inhibitors in development include AstraZeneca's olaparib and Abbott Laboratories' veliparib. Sales of agents targeting HER2-positive breast cancer will increase by almost $2 billion through 2019. This growth will be fueled by the increased uptake of Roche/Chugai's Herceptin, GlaxoSmithKline's Tykerb/Tyverb and the approval of three new HER2-targeted therapies -- Roche/Genentech/Chugai's trastuzumab-DM1, Roche/Chugai's Omnitarg and Pfizer's neratinib.

The Pharmacor 2010 findings also reveal that Roche/Genentech/Chugai's Avastin has garnered substantial patient share, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where effective therapies are few. However, in July 2010, Avastin's future in this indication was cast in doubt after the Oncologic Drugs Advisory Commission recommended that the FDA rescind the agent's conditional approval for first-line metastatic HER2-negative breast cancer. Additionally, Avastin's European label for breast cancer is also under review by the European Medicines Agency.

"The fact that the National Comprehensive Cancer Network guidelines panel for breast cancer recently aff
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
2. FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
3. Nanoelectronic transistor combined with biological machine could lead to better electronics
4. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
5. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
6. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
7. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
8. Microbix Has Best-Ever Quarterly Sales
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
11. Dynamic Ventures Corporation enters into a long-term agreement that brings $50 million annual sales opportunity for wholly owned subsidiary EZ-Build.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased ... office in Charlottetown , PEI.  Bioenterprise ... Edward Island ADAPT Council for the commercialization of agricultural ... to working with PEI ADAPT.  They have been at ... than a decade," explains Dave Smardon , President ...
(Date:4/16/2015)... DIEGO , April 16, 2015 Avelas ... dedicated to improving cancer surgeries, announced today that it ... fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent ... the company also welcomed the addition of Steven ... The open label, dose escalation study will ...
(Date:4/16/2015)... 16, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... non-toxic DCVax® personalized immune therapies for cancer, announced ... Loncar Cancer Immunotherapy Index (LCINDX), a professional index ... immunotherapy field within the biotechnology space.  ... 25 companies" in the immunotherapy space, including 6 ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... 6, 2011 SyntheMed, Inc. ("the Company") (OTCBB: SYMD; Pink ... biotechnology company focused on the treatment of diseases characterized by ... effective September 2, 2011.  The Company changed its name to ... trade on the OTC Bulletin Board, changing to a new ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... Vice President, General Counsel and Secretary.  Mr. LaRosa will ... affairs, including general corporate legal matters, intellectual property and ... M.D., Ph.D., president and chief executive officer. ...
... Genprex, Inc., formerly known as Convergen LifeSciences, ... cancer therapy CNVN202, will be branded as Oncoprex™ . ... brand in the oncology sector in recognition of our advancing ... will be used to unlock the unrealized potential of a ...
Cached Biology Technology:Pathfinder, LLC and SyntheMed, Inc. Complete Merger 2Pathfinder, LLC and SyntheMed, Inc. Complete Merger 3Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary 2Genprex Announces New Branding 2
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Two junior researchers from Ludwig-Maximilians-Universitt (LMU) in Munich ... European Research Council (ERC). Professor Jens Michaelis, Department ... Vhringer, Institute of Immunology, shall receive grants amounting ... years. With its Starting Grant, the ERC supports ...
... DALLAS Oct. 27, 2009 UT Southwestern Medical ... Texas to receive the newest generation of a mechanical device ... while he awaits a heart transplant. Called a left-ventricular ... weakened heart pump blood throughout the body. For Mr. LeBlanc, ...
... WALL, N.J., Oct. 26 BIO-key International, Inc. (OTC ... software is showcasing donor and patient identity solutions at ... Orleans Convention Center from October 25-27 2009. BIO-key will ... in booth #424. Also, at 5 PM on Monday, ...
Cached Biology News:LMU Munich researchers highly endowed with EU funding 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3BIO-key(R) International Exhibiting at AABB TXPO 2
Request Info...
384 Cluster Tube Racks...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
... Immunogen: Partially purified chicken ... detects vitamin D receptor (VDR) from ... and fish tissues. This antibody ... glucocorticoid receptors. MA1-710 detects both ...
Biology Products: